CHICAGO--(BUSINESS WIRE)-- Tempus AI, Inc. (TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today announced a collaboration to develop a companion ...

Dr. Madhuri Hegde explores the changing landscape of CDx, the technologies accelerating its progress, and the challenges ...

In the dynamic world of life sciences, digital pathology stands out as a beacon of innovation, promising transformative changes in how pathologists engage, evaluate, and collaborate. In this episode, ...

Partnerships in healthcare have never been more important. Through collaboration, industry specialists are increasingly bringing cutting-edge medical innovations and life-changing treatments to ...

SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies Inc. (NYSE: A) today announced a strategic partnership with PathAI, a leading provider of AI-powered research tools and services for ...

Next-generation-sequencing-based homologous recombination deficiency (HRD) assay based on QIAGEN’s QIAseq xHYB technology, QIAGEN Digital Insight solutions, and Myriad’s proprietary, FDA-approved ...

A CDx assay is an important treatment decision tool that needs to be available simultaneously with the drug. However, within the past few years, several targeted drugs and new indications have been ...

Companion diagnostics (CDx) facilitate the use of more targeted treatment options for patients. However, developing and getting them approved can be a complex process. Effective development must ...

(RTTNews) - Agilent Technologies Inc. (A) announced an agreement with Incyte that will bring together Agilent's expertise in the development of companion diagnostics to support the development and ...

Invivoscribe, a leader in precision medicine and measurable residual disease (MRD) testing, today announced the addition of the LeukoStrat(R) KMT2A + MRD Assay and Software to its industry-leading ...